Who are Hylan GF-20 alone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Synvisc-One, Hyaluronic acid (HA), Hyaluronic Acid Injection, Hyalgan (sodium hyaluronate), viscosupplementation 1+1+1, injection of hyaluronic acid..

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hylan-gf-20-alone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Hylan GF-20 alone — Competitive Intelligence Brief

Hylan GF-20 alone (Hylan GF-20 alone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viscosupplement. Area: Rheumatology / Orthopedics.

marketed Viscosupplement Hyaluronic acid receptor (CD44) Rheumatology / Orthopedics Small molecule Live · refreshed every 30 min

Target snapshot

Hylan GF-20 alone (Hylan GF-20 alone) — University of Sao Paulo General Hospital. Hylan GF-20 is a viscoelastic gel that lubricates and cushions the joint space to reduce friction and pain in osteoarthritis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Hylan GF-20 alone TARGET	Hylan GF-20 alone	University of Sao Paulo General Hospital	marketed	Viscosupplement	Hyaluronic acid receptor (CD44)
Synvisc-One	Synvisc-One	Nature Cell Co. Ltd.	marketed	Viscosupplement; hyaluronic acid derivative	Synovial fluid; joint cartilage surfaces
Hyaluronic acid (HA)	Hyaluronic acid (HA)	Chinese University of Hong Kong	marketed	Viscosupplement / Biological polymer
Hyaluronic Acid Injection	Hyaluronic Acid Injection	Wroclaw Medical University	marketed	Viscosupplement
Hyalgan (sodium hyaluronate)	Hyalgan (sodium hyaluronate)	Sanofi	marketed	Viscosupplement	Synovial fluid replacement (non-receptor mediated)
viscosupplementation 1+1+1	viscosupplementation 1+1+1	University of Sao Paulo General Hospital	marketed	Hyaluronic acid derivative; viscosupplement	Hyaluronic acid receptor (CD44); joint synovial fluid
injection of hyaluronic acid.	injection of hyaluronic acid.	Istituto Ortopedico Rizzoli	marketed	Viscosupplement	Joint synovial fluid (viscoelastic properties)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viscosupplement class)

Istituto Ortopedico Rizzoli · 1 drug in this class
LG Life Sciences · 1 drug in this class
ProChon Biotech Ltd · 1 drug in this class
Sanofi · 1 drug in this class
Taipei Medical University · 1 drug in this class
University of Sao Paulo General Hospital · 1 drug in this class
Wroclaw Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hylan GF-20 alone — Competitive Intelligence Brief. https://druglandscape.com/ci/hylan-gf-20-alone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab